Gilead's Sofosbuvir for Hepatitis C M...

Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

There are 1 comment on the Drugs.com story from Feb 19, 2013, titled Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study. In it, Drugs.com reports that:

Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.

Join the discussion below, or Read more at Drugs.com.

Axel

Bucharest, Romania

#1 Feb 19, 2013
Thank God, thank God and good doctors

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
News Appalachian congressmen ask FDA to reclassify O... (May '07) 28 min Ron Paul Liberty 37
News CDC panel again advises against FluMist Jun 22 VACCINES MAIM KILL 1
News Gov't report: Efforts to reduce US uninsured st... May '17 kuda 22
News Ring-ring: Cellphone interrupts Supreme Court h... Apr '17 better call Saul 1
News Mumps outbreak probably isn't related to vaccin... Apr '17 MMR 1
News Bristol Palin says abstinence best path for teens (May '09) Apr '17 Coonway Tweety 2,658
News After Trump rally, equity investors move into h... Mar '17 Retribution 6
More from around the web